Download Databook
Download Sample
NA : +1 804 441 9344
sales@towardshealthcare.com
Schedule a Meeting
June 2025
The next-gen proteomics market is rapidly advancing on a global scale, with expectations of accumulating hundreds of millions in revenue between 2025 and 2034. Market forecasts suggest robust development fueled by increased investments, innovation, and rising demand across various industries.
The global next-gen proteomics market is experiencing major growth due to factors such as the growing number of chronic disease cases, including cardiovascular conditions, autoimmune disorders, and neurological diseases, which require highly efficient personalized medicine based on individual characteristics. Moreover, various technological advancements like NGS (next-generation sequencing), mass spectrometry, and chromatography techniques are fueling market growth. Also, accelerating the drug discovery process to develop targeted therapies is encouraging investments in the R&D of proteomics.
| Metric | Details |
| Important Highligts | NA led in 2024, APAC growing fastest, Mass spectrometry led tech, Protein microarrays growing fastest, Instruments led, Software growing fastest |
| End User Insights | Pharma & biotech led in 2024, Diagnostic labs to grow fastest |
| Recent Trends | Syncell & Spear Bio secured funding & partnerships in 2024–2025 |
| Market Driver | Rising demand for personalized medicine and drug discovery |
| Market Restraint | High costs of instruments and data complexity |
| Market Opportunity | Advances in tech like mass spectrometry, microarrays, and bioinformatics |
Next-generation proteomics is one of the advanced technologies and methodologies that provides complete analysis of the proteome, the overall set of proteins in a cell or living organism. Most widely used mass spectrometry and novel bioinformatics enable the description of protein expression, structure, and interactions on a huge scale, such as post-translational modifications. The next-generation proteomics market is highly propelled by the accelerating advancements in technologies, increasing developments for personalized medicine, along with this, boosting numerous approaches in drug discovery, and growing public and private investments in research and development of infrastructure.
AI in the respective market provides interpretation of a huge volume of data generated by different technologies, like mass spectrometry and other proteomic techniques. Also, it helps in the identification of subtle patterns and biomarkers indicative of diseases, drug responses, or biological processes. Moreover, AI algorithms unite proteomics data along with other omics data, including genomics, transcriptomics, to allow a more holistic view of biological systems.
For instance,
Growing Demand for Personalized Medicines and the Drug Discovery Process
Globally, nowadays, the next-gen proteomics market growth is driven by the rise of different health conditions requiring tailored medicines based on individual characteristics, in which proteomics plays a major role in the detection of disease-specific biomarkers, recognizing individual protein profiles, and advancing targeted therapies, acting as key components of personalized medicine. Besides this, the rising instrumental target validation, MOA studies, and identification of robust drug candidates, simplifying the drug development process.
Boosting the Expenditure on Instruments and Consumables
In the next-gen proteomics market, growing challenges are the increasing expenses on advanced technologies such as mass spectrometers and chromatography systems, with raised spending on their installation and maintenance. This expense generates hurdles for small-scale research labs, academic institutions, and companies. Another is the rising need for expertise to analyze the vast amounts of data and manage complexity.
Progressing Technological Advancements and Bioinformatics
In the upcoming era, different kinds of opportunities are growing, such as innovations in various technologies, including mass spectrometry, protein microarrays, and NGS, which are improving accuracy and acquisition in both research and clinical settings. Moreover, breakthroughs in single-cell analysis and bioinformatics are providing more detailed and complete next-gen proteomic studies.
By technology, the mass spectrometry segment held the dominating revenue share of the market in 2024. The segment is driven by rising technological advancements, increasing demand for personalized medicines, and enhanced techniques in protein quantification and identification, including 4D proteomics, single-cell proteomics, which also boosts the adoption of mass spectrometry in next-generation proteomics research.
By technology, the protein microarrays segment is expected to grow rapidly during the forecast period. The rising chronic disease cases, growing personalized medicines demand, and breakthroughs in technologies are widely impacting the next-gen proteomics market growth. Furthermore, the segment is expanding due to the accelerating adoption of biomarker discovery, high-throughput screening, and prior disease detection.
By product & service, the instruments segment led the market in 2024. Along with technological advancements and the drug discovery process, other factors such as rising investments in proteomics R&D and declining expenses of next-generation sequencing (NGS) technologies are escalating their adoption in different approaches, fueling the segment growth.
The software segment is expected to grow at the fastest CAGR in the coming years. The advancing next-generation proteomics technologies, including mass spectrometry and high-throughput screening, are generating large and complex datasets. These datasets require sophisticated software for analysis and interpretation, which results in the demand for specialized bioinformatics tools. Although this software simplifies the workflows, enhances data analysis efficiency, and is user-friendly, it is a plus.
By application, the drug discovery segment held the dominating revenue share of the market in 2024. Due to the analysis of protein expression and interactions, proteomics assists in the identification of specific protein targets for drug intervention, which accelerates the development of targeted therapies with enhanced efficiency. Also, drug discovery supports in finding targets with their cellular pathways effects, with the enhancement of drug efficacy and the reduction of side effects.
By application, the personalized medicine segment is expected to grow fastest during the forecast period. Nowadays, numerous diseases are growing, such as cancer, autoimmune conditions, and cardiovascular diseases, which need customized therapies that rely on individual genetic and proteomic profiles are majorly driving the expansion of the market.
By end user, the pharmaceutical & biotechnology companies segment led the next-gen proteomics market in 2024. The segment is driven by the rising adoption of drug discovery and personalized medicine. Along with this, growing advancements in technologies are being acquired by many pharmaceutical & biotechnology companies are contributing to the development of next-generation proteomics.
By end user, the diagnostic laboratories segment is expected to grow fastest in the studied years. The expansion of the segment is based on growing advancements in Next-generation sequencing (NGS), CRISPR, and other molecular biology techniques, which enable rapid, affordable, and accurate diagnostic tests, ultimately resulting in early detection of disease and potential personalized choices.
North America led the global next-gen proteomics market by capturing the largest revenue share in 2024. The market is propelled by the rising chronic diseases, including age-related disorders, neurological diseases, autoimmune diseases, and cancer, along with increasing well-established healthcare infrastructure and a strong life sciences area. As well as respective governments are encouraging investments in proteomic R&D approaches.
In the US, the market is driven by accelerating technological advancements like NGS and mass spectrometry, which are boosting the potential and applications of proteomics. Besides this, the major population of this country is demanding precision medicine with the identification of disease biomarkers and drug targets.
Canada, with raised government initiatives and private sector investments, is propelling research and development in next-gen proteomics in domains such as biomarker identification and drug discovery, driving the market growth.
Asia Pacific is expected to grow at the fastest CAGR in the upcoming years. This regional market is driven by several factors, with the majorly contributor being the rise in the number of cases of chronic diseases, including heart conditions, diabetes, autoimmune disorders, and neurological diseases. Along with this, raised cases are demanding highly efficient personalized medicines in proteomics.
China is experiencing crucial growth due to boosting innovations in technologies like NGD, mass spectrometry, and bioinformatics, which help in the optimization of sensitivity, precision, and throughput of proteomic analysis. Also, there are surging clinical trials and conventional research efforts that are demanding of proteomics.
The market in India is propelled by the development of biologics and biosimilars, with its increased application in biomarker discovery for disease detection and prognosis acting as major growth factors. As well as India is accelerating collaborations, partnerships with biopharmaceutical industries, hospitals, and research academics are involved as fuel for market growth.
In Europe, the significant market growth is impelled by the rising awareness about its adoption in different areas such as oncology, neurology, immunology, and pathology. Also, the advancements in bioinformatics tools and computational techniques are allowing researchers the analyze and interpret complex proteomic data, which is fueling the expansion of the market.
Various academic institutions, biotechnology and pharmaceutical companies with government funding are participating in research activities of proteomics are fueling the market growth.
The UK is facing major growth due to the increasing incidence of chronic diseases, the accelerating demand for precision medicines, and the advancements in proteomics technologies.
By Technology
By Product & Service
By Application
By End User
By Region
June 2025
June 2025
June 2025
June 2025